title: Concurrent chemo- and radiotherapy in patients with locally advanced carcinoma of the cervix.
abstract: BACKGROUND
  The feasibility of concurrent chemotherapy and radiotherapy for advanced primary carcinoma of the cervix was evaluated and the results were compared to historical controls.
  
  
  METHODS
  In a single institution study, patients (n = 74) with primary cervical carcinoma received 3 cycles carboplatin/5-fluorouracil concurrent with radiotherapy followed by salvage hysterectomy (group I). Treatment results were compared with those of a historical control group (n = 39) (group II), treated similarly but without chemotherapy.
  
  
  RESULTS
  In group I median follow-up is 28 months (12-68+) and in group II 23 months (14-90+ months). The 5-year overall survival, progression-free survival and local recurrence free survival for group I and II are, respectively, 69% versus 38% (P < 0.003), 67% versus 38% (P < 0.005) and 84% versus 43% (P < 0.0001). Two patients in each group developed posttreatment enteritis.
  
  
  CONCLUSIONS
  Radiotherapy with concurrent carboplatin and 5-fluorouracil resulted in a better overall survival, disease free survival and local disease free survival compared to historical controls. The toxicity of this schedule did not exceed that of radiation alone in historical controls.
authors.forename: E
authors.initials: E
authors.lastname: Pras
authors.forename: P H
authors.initials: PH
authors.lastname: Willemse
authors.forename: H
authors.initials: H
authors.lastname: Boonstra
authors.forename: H
authors.initials: H
authors.lastname: Hollema
authors.forename: M A
authors.initials: MA
authors.lastname: Heesters
authors.forename: B G
authors.initials: BG
authors.lastname: Szabó
authors.forename: H W
authors.initials: HW
authors.lastname: de Bruijn
authors.forename: J G
authors.initials: JG
authors.lastname: Aalders
authors.forename: E G
authors.initials: EG
authors.lastname: de Vries
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use; D016009:Chi-Square Distribution; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D000964:Antimetabolites, Antineoplastic; D016190:Carboplatin; D005472:Fluorouracil